GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » Machinery, Furniture, Equipment

Erasca (Erasca) Machinery, Furniture, Equipment : $5.77 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Erasca Machinery, Furniture, Equipment?

Erasca's Machinery, Furniture, Equipment for the quarter that ended in Dec. 2023 was $5.77 Mil.

Erasca's quarterly Machinery, Furniture, Equipment stayed the same from Jun. 2023 ($5.76 Mil) to Sep. 2023 ($5.76 Mil) but then increased from Sep. 2023 ($5.76 Mil) to Dec. 2023 ($5.77 Mil).

Erasca's annual Machinery, Furniture, Equipment increased from Dec. 2021 ($3.17 Mil) to Dec. 2022 ($5.66 Mil) and increased from Dec. 2022 ($5.66 Mil) to Dec. 2023 ($5.77 Mil).


Erasca Machinery, Furniture, Equipment Historical Data

The historical data trend for Erasca's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Erasca Machinery, Furniture, Equipment Chart

Erasca Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Machinery, Furniture, Equipment
0.41 0.57 3.17 5.66 5.77

Erasca Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Machinery, Furniture, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.66 5.71 5.76 5.76 5.77

Erasca Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.


Erasca (Erasca) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Executives
Jonathan E Lim director, 10 percent owner, officer: See Remarks 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding director C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Shannon Morris officer: Chief Medical Officer C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp director 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp director 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp director 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu director 21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner officer: General Counsel C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Lim Conyee T. 10 percent owner C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121
Arch Venture Fund X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Erasca (Erasca) Headlines

From GuruFocus

Erasca Announces Pricing of Underwritten Offering of Common Stock

By Value_Insider Value_Insider 12-09-2022

Erasca to Present at the Guggenheim Oncology Conference 2023

By Stock market mentor Stock market mentor 02-01-2023

Could Insider Buying Signal that Erasca Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 12-16-2022